Woodstock Corp Buys 42,310 Shares of OmniAb, Inc. (NASDAQ:OABI)

Woodstock Corp boosted its position in shares of OmniAb, Inc. (NASDAQ:OABIFree Report) by 5.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 792,853 shares of the company’s stock after buying an additional 42,310 shares during the quarter. Woodstock Corp’s holdings in OmniAb were worth $3,354,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of OABI. SG Americas Securities LLC boosted its holdings in OmniAb by 105.6% during the third quarter. SG Americas Securities LLC now owns 34,858 shares of the company’s stock valued at $147,000 after purchasing an additional 17,901 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of OmniAb during the second quarter valued at $147,000. Squarepoint Ops LLC acquired a new stake in shares of OmniAb in the 2nd quarter valued at $449,000. Sei Investments Co. grew its holdings in shares of OmniAb by 11.0% in the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after purchasing an additional 2,888 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in OmniAb by 6.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after purchasing an additional 194,835 shares during the last quarter. Institutional investors and hedge funds own 72.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on OABI shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price objective on shares of OmniAb in a research note on Friday, August 16th. Benchmark restated a “buy” rating and set a $8.00 price target on shares of OmniAb in a research report on Monday, August 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a research report on Monday, August 12th.

Check Out Our Latest Stock Report on OABI

OmniAb Trading Up 3.1 %

Shares of NASDAQ OABI opened at $4.04 on Monday. OmniAb, Inc. has a 1-year low of $3.56 and a 1-year high of $6.72. The company has a 50-day moving average of $4.21 and a two-hundred day moving average of $4.42. The company has a market cap of $475.16 million, a PE ratio of -6.31 and a beta of -0.13.

OmniAb (NASDAQ:OABIGet Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. The firm had revenue of $7.61 million during the quarter, compared to analysts’ expectations of $6.52 million. OmniAb had a negative net margin of 287.29% and a negative return on equity of 20.21%. During the same quarter in the previous year, the company posted ($0.15) EPS. As a group, equities research analysts forecast that OmniAb, Inc. will post -0.58 earnings per share for the current year.

OmniAb Profile

(Free Report)

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.

Further Reading

Want to see what other hedge funds are holding OABI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OmniAb, Inc. (NASDAQ:OABIFree Report).

Institutional Ownership by Quarter for OmniAb (NASDAQ:OABI)

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.